Borregaard ASA (BRGAY) Discusses BioSolutions Segment Outlook and Margin Dynamics Ahead of Close December 18, 2025 8:00 AM EST
Company Participants
Veronica Skevik – Vice President of Finance
Per Bjarne Lyngstad – CFO & Interim Director of Investor Relations
Presentation
Veronica Skevik
Vice President of Finance
Good [ morning ] everyone. Thank you for joining Borregaard’s pre-close call. My name is Veronica Skevik Frey and I am Vice President Finance in Borregaard. I’m joined today by our CFO, Per Bjarne Lyngstad, and we are live from the biorefinery in Norway. And here is the agenda for today’s call. First, we’ll look at the outlook from the latest quarterly report from the Q3 report reiterated for that. Secondly, currency and commodities inputs and then last, we’ll have a Q&A session. And regarding the Q&A session, feel free to start typing your questions in the chat functions. And now I will hand over to Per Bjarne, who will then reiterate the key points from the outlook given in our third quarterly report.
Per Bjarne Lyngstad
CFO & Interim Director of Investor Relations
Thank you, Veronica, and good afternoon, everyone. I will start with reiterating the key points from the outlook for Q4 and when relevant refer to comments given in the Q&A session at the webcast for the third quarter on the 22nd of October this year. I will start with BioSolutions. In Biosolutions, we expect the sales volume in the fourth quarter to be between 70,000 and 75,000 tonnes which is below the 77,000 tonnes we had in the fourth quarter last year.
We continue to expect a positive but limited effect from the antidumping duties on vending. We’ve got 3 questions regarding BioSolutions at the webcast after the third quarter. The first core question was related to margin development and the decline year-on-year
